Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.
The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4(+) T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4(+) T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4(+) T cells in increasing HIV-1 susceptibility in the STEP trial.
Hutnick
Natalie A
NA
Department of Microbiology and Center for AIDS Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Carnathan
Diane G
DG
Dubey
Sheri A
SA
Makedonas
George
G
Cox
Kara S
KS
Kierstead
Lisa
L
Ratcliffe
Sarah J
SJ
Robertson
Michael N
MN
Casimiro
Danilo R
DR
Ertl
Hildegund C J
HC
Betts
Michael R
MR
D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D000256:Adenoviridae / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D011379:Prognosis; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D014614:Vaccines, Synthetic